Quanterix to Present at Leerink Partners Healthcare Crossroads Conference 2024

Rhea-AI Summary

Quanterix (NASDAQ: QTRX), a leader in biomarker detection technology, announced that its CEO, Masoud Toloue, will participate in a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference. The presentation is scheduled for May 29, 2024, at 11:40 a.m. ET and will be available via a live webcast.

Replays will be accessible for a time post-conference. For more details, visit Quanterix’s official website.

Positive

• CEO Masoud Toloue will represent Quanterix at a high-profile healthcare conference.
• The event offers a platform to highlight Quanterix’s advancements in biomarker detection.
• Webcast availability increases accessibility for a broader audience.

Negative

• No new financial or clinical data were disclosed in the announcement.
• Potential investor disappointment if significant updates or insights are not provided during the fireside chat.

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak in a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference. Quanterix’s presentation is scheduled for Wednesday, May 29, 2024, at 11:40 a.m. ET. The fireside chat will be made available to attendees and to the public via webcast.

Webcast Information
The live webcast of Quanterix’s presentation can be accessed here, and from the Investor section of the company' website at www.Quanterix.com. Replays of the presentation will be available for a limited time following the conference.

To learn more about Quanterix, visit www.quanterix.com/about. To learn more about Quanterix’s Simoa® technology, visit: www.quanterix.com/simoa-technology/.

About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa ® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522008584/en/

Media Contact:

PAN Communications

Maya Nimnicht

510-334-6273

quanterix@pancomm.com

Investor Relations Contact:

Quanterix

Francis Pruell

(508)-789-1725

ir@quanterix.com

Source: Quanterix Corporation

FAQ

When is Quanterix presenting at the 2024 Leerink Partners Healthcare Crossroads Conference?

Quanterix will present on May 29, 2024, at 11:40 a.m. ET.

How can I watch the Quanterix presentation at the Leerink Partners Healthcare Crossroads Conference?

The presentation will be available via live webcast accessible through Quanterix’s website.

Who will represent Quanterix at the 2024 Leerink Partners Healthcare Crossroads Conference?

CEO Masoud Toloue will represent Quanterix.

What is the focus of Quanterix's presentation at the Leerink Partners Healthcare Crossroads Conference?

The focus will be on discussing advancements and updates in biomarker detection technology.

Is there a replay available for Quanterix's presentation at the Leerink Partners Healthcare Crossroads Conference?

Yes, replays will be available for a time following the conference.